ARTICLE | Company News
Variagenics and Boehringer in pharmacogenomics deal
September 21, 2000 7:00 AM UTC
VGNX will use its Variagenic Impact Program to perform custom SNP discovery on an undisclosed therapeutic candidate from Boehringer Ingelheim Pharmaceuticals (Ridgefield, Conn.) in order to identify g...